{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:03:25Z","timestamp":1792029805918,"version":"4.4.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>The study aims to verify the advantages of nonsteroidal mineralocorticoid receptor blockers (MRBs) in the management of hypertension and cardiovascular and renal diseases, comparing with conventional MRBs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Based on the unique structures, the nonsteroidal MRBs have higher selectivity for mineralocorticoid receptors (MRs) and show no agonist activity for major steroid hormone receptors in contrast to steroidal MRBs. Today, there are two nonsteroidal MRBs, esaxerenone and finerenone, which completed phase 3 clinical trials. Series of clinical trials have shown that both agents achieve similar MR blockade with smaller doses as compared with steroidal MRBs, but have no off-target side effect such as gynecomastia. Esaxerenone has persistent blood pressure-lowering effects in various hypertensive populations, including essential hypertension and those with diabetes and\/or chronic kidney disease, while finerenone has demonstrated reduction of the cardiovascular risk rather than blood pressure in patients with diabetes and chronic kidney disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Nonsteroidal MRBs are a more refined agent which contributes to appropriate MR blocking with minimized unpleasant adverse effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11906-022-01177-6","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T07:02:43Z","timestamp":1651302163000},"page":"215-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers"],"prefix":"10.1007","volume":"24","author":[{"given":"Yuta","family":"Tezuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadayoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"issue":"10008","key":"1177_CR1","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(15)00257-3.","journal-title":"Lancet"},{"issue":"3","key":"1177_CR2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jchf.2019.09.011","volume":"8","author":"M Serenelli","year":"2020","unstructured":"Serenelli M, Jackson A, Dewan P, Jhund PS, Petrie MC, Rossignol P, et al. Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC Heart Fail. 2020;8(3):188\u201398. https:\/\/doi.org\/10.1016\/j.jchf.2019.09.011.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"1177_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492.","journal-title":"N Engl J Med"},{"issue":"6","key":"1177_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","volume":"6","author":"B Williams","year":"2018","unstructured":"\u2022 Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6(6):464\u201375. https:\/\/doi.org\/10.1016\/S2213-8587(18)30071-8. This subanalysis of the PATHWAY-2 study indicates that spironolactone lowers blood pressure regardless of plasma aldosterone levels in resistant hypertension.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"17","key":"1177_CR5","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","volume":"62","author":"R Eschalier","year":"2013","unstructured":"Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol. 2013;62(17):1585\u201393. https:\/\/doi.org\/10.1016\/j.jacc.2013.04.086.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1177_CR6","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/cjn.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1(5):940\u201351. https:\/\/doi.org\/10.2215\/cjn.00240106.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"1177_CR7","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1093\/ajh\/hpv031","volume":"28","author":"K Dahal","year":"2015","unstructured":"Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens. 2015;28(11):1376\u201385. https:\/\/doi.org\/10.1093\/ajh\/hpv031.","journal-title":"Am J Hypertens"},{"issue":"6","key":"1177_CR8","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","volume":"42","author":"JGF Cleland","year":"2021","unstructured":"Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, et al. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial. Eur Heart J. 2021;42(6):684\u201396. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa758.","journal-title":"Eur Heart J"},{"issue":"3281","key":"1177_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1126\/science.126.3281.1015","volume":"126","author":"CM Kagawa","year":"1957","unstructured":"Kagawa CM, Cella JA, Van Arman CG. Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science. 1957;126(3281):1015\u20136. https:\/\/doi.org\/10.1126\/science.126.3281.1015.","journal-title":"Science"},{"issue":"4","key":"1177_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/jdi.12629","volume":"8","author":"LJ Sun","year":"2017","unstructured":"Sun LJ, Sun YN, Shan JP, Jiang GR. Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy. J Diabetes Investig. 2017;8(4):609\u201318. https:\/\/doi.org\/10.1111\/jdi.12629.","journal-title":"J Diabetes Investig"},{"key":"1177_CR11","doi-asserted-by":"publisher","unstructured":"Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind reminder study. Eur Heart J. 2014;35(34):2295\u2013302. https:\/\/doi.org\/10.1093\/eurheartj\/ehu164.","DOI":"10.1093\/eurheartj\/ehu164"},{"issue":"12","key":"1177_CR12","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jchf.2019.08.017","volume":"7","author":"JP Ferreira","year":"2019","unstructured":"Ferreira JP, Rossello X, Eschalier R, McMurray JJV, Pocock S, Girerd N, et al. MRAs in elderly HF patients: individual patient-data meta-analysis of RALES, EMPHASIS-HF, and TOPCAT. JACC Heart Fail. 2019;7(12):1012\u201321. https:\/\/doi.org\/10.1016\/j.jchf.2019.08.017.","journal-title":"JACC Heart Fail"},{"key":"1177_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","volume":"200","author":"M Lainscak","year":"2015","unstructured":"Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, et al. Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol. 2015;200:25\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.127.","journal-title":"Int J Cardiol"},{"issue":"1","key":"1177_CR14","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Barfacker L. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234(1):T125\u201340. https:\/\/doi.org\/10.1530\/JOE-16-0600.","journal-title":"J Endocrinol"},{"issue":"46","key":"1177_CR15","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.2174\/1381612825666190222144359","volume":"24","author":"MS Kallistratos","year":"2018","unstructured":"Kallistratos MS, Pittaras A, Theodoulidis I, Grassos C, Poulimenos LE, Manolis AJ. Adverse effects of mineralocorticoid receptor antagonist administration. Curr Pharm Des. 2018;24(46):5537\u201341. https:\/\/doi.org\/10.2174\/1381612825666190222144359.","journal-title":"Curr Pharm Des"},{"key":"1177_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015;761:226\u201334. https:\/\/doi.org\/10.1016\/j.ejphar.2015.06.015.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"1177_CR17","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L B\u00e4rfacker","year":"2012","unstructured":"B\u00e4rfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-P\u00e9rez S, Heckroth H, et al. Discovery of BAY 94\u20138862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385\u2013403. https:\/\/doi.org\/10.1002\/cmdc.201200081.","journal-title":"ChemMedChem"},{"issue":"4","key":"1177_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","volume":"79","author":"S Duggan","year":"2019","unstructured":"Duggan S. Esaxerenone: first global approval. Drugs. 2019;79(4):477\u201381. https:\/\/doi.org\/10.1007\/s40265-019-01073-5.","journal-title":"Drugs"},{"issue":"8","key":"1177_CR19","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/bcp.13616","volume":"84","author":"M Kato","year":"2018","unstructured":"Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F, Ishizuka H. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol. 2018;84(8):1821\u20139. https:\/\/doi.org\/10.1111\/bcp.13616.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1177_CR20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","volume":"33","author":"S Ito","year":"2019","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study. J Hum Hypertens. 2019;33(7):542\u201351. https:\/\/doi.org\/10.1038\/s41371-019-0207-x.","journal-title":"J Hum Hypertens"},{"issue":"12","key":"1177_CR21","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","volume":"42","author":"H Rakugi","year":"2019","unstructured":"Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res. 2019;42(12):1932\u201341. https:\/\/doi.org\/10.1038\/s41440-019-0314-7.","journal-title":"Hypertens Res"},{"issue":"1","key":"1177_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/hypertensionaha.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"\u2022\u2022 Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study). Hypertension. 2020;75(1):51\u20138. https:\/\/doi.org\/10.1161\/hypertensionaha.119.13569. This paper demonstrates the solid antihypertensive effect of esaxerenone followed by no sexual adverse event in essential hypertension. The blood pressure-lowering effect of 2.5 mg daily esaxerenone was noninferior to that of 50 mg daily eplerenone.","journal-title":"Hypertension"},{"issue":"12","key":"1177_CR23","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/cjn.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"\u2022\u2022 Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol. 2020;15(12):1715\u201327. https:\/\/doi.org\/10.2215\/cjn.06870520. This paper shows that esaxerenone use dramatically reduces urinary albumin excretion in diabetic petients treated with renin-angiotensin system inhibitors.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1177_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41440-020-00585-y","volume":"44","author":"S Ito","year":"2021","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Iijima S. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction. Hypertens Res. 2021;44(5):489\u201397. https:\/\/doi.org\/10.1038\/s41440-020-00585-y.","journal-title":"Hypertens Res"},{"issue":"31","key":"1177_CR25","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363. https:\/\/doi.org\/10.1093\/eurheartj\/eht187.","journal-title":"Eur Heart J"},{"key":"1177_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.04.079","author":"G Filippatos","year":"2021","unstructured":"\u2022 Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, et al. Finerenone reduces onset of atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J Am Coll Cardiol. 2021. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.079. This subanalysis of the FIDELIO-DKD trial shows that finerenone has a preventive effect on new onset of atrial fibrillation in diabetic patients with chronic kidney disease.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"1177_CR27","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"\u2022\u2022 Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845. This large randomized cohort elucidates that finerenone significantly reduces cardiac and renal risks with mild improvement of blood pressure in diabetic patients with chronic kidney disease.","journal-title":"N Engl J Med"},{"key":"1177_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coph.2016.02.005","volume":"27","author":"J Yang","year":"2016","unstructured":"Yang J, Young MJ. Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences. Curr Opin Pharmacol. 2016;27:78\u201385. https:\/\/doi.org\/10.1016\/j.coph.2016.02.005.","journal-title":"Curr Opin Pharmacol"},{"issue":"10","key":"1177_CR29","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/1873-3468.13746","volume":"594","author":"M Takahashi","year":"2020","unstructured":"\u2022 Takahashi M, Ubukata O, Homma T, Asoh Y, Honzumi M, Hayashi N, et al. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150). FEBS Lett. 2020;594(10):1615\u201323. https:\/\/doi.org\/10.1002\/1873-3468.13746. This paper reveals the unique binding mode of esaxerenone to mineralocorticoid receptors.","journal-title":"FEBS Lett"},{"issue":"36","key":"1177_CR30","doi-asserted-by":"publisher","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","volume":"290","author":"L Amazit","year":"2015","unstructured":"Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR, et al. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem. 2015;290(36):21876\u201389. https:\/\/doi.org\/10.1074\/jbc.M115.657957.","journal-title":"J Biol Chem"},{"issue":"4","key":"1177_CR31","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","volume":"29","author":"P Gardiner","year":"1989","unstructured":"Gardiner P, Schrode K, Quinlan D, Martin BK, Boreham DR, Rogers MS, et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol. 1989;29(4):342\u20137. https:\/\/doi.org\/10.1002\/j.1552-4604.1989.tb03339.x.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"1177_CR32","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","volume":"31","author":"CS Cook","year":"2003","unstructured":"Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, Liu NW. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos. 2003;31(11):1448\u201355. https:\/\/doi.org\/10.1124\/dmd.31.11.1448.","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"1177_CR33","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1124\/dmd.118.083337","volume":"46","author":"M Gerisch","year":"2018","unstructured":"Gerisch M, Heinig R, Engelen A, Lang D, Kolkhof P, Radtke M, et al. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro. Drug Metab Dispos. 2018;46(11):1546\u201355. https:\/\/doi.org\/10.1124\/dmd.118.083337.","journal-title":"Drug Metab Dispos"},{"key":"1177_CR34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","volume":"769","author":"K Arai","year":"2015","unstructured":"Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015;769:266\u201373. https:\/\/doi.org\/10.1016\/j.ejphar.2015.11.028.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1177_CR35","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1124\/jpet.116.234765","volume":"358","author":"K Arai","year":"2016","unstructured":"Arai K, Morikawa Y, Ubukata N, Tsuruoka H, Homma T. CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate\/salt-induced hypertensive rats. J Pharmacol Exp Ther. 2016;358(3):548\u201357. https:\/\/doi.org\/10.1124\/jpet.116.234765.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1177_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152\u201361. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa736.","journal-title":"Eur Heart J"},{"issue":"12","key":"1177_CR37","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1080\/00498254.2016.1263766","volume":"47","author":"M Yamada","year":"2017","unstructured":"Yamada M, Takei M, Suzuki E, Takakusa H, Kotsuma M, Washio T, et al. Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys. Xenobiotica. 2017;47(12):1090\u2013103. https:\/\/doi.org\/10.1080\/00498254.2016.1263766.","journal-title":"Xenobiotica"},{"issue":"1","key":"1177_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/fjc.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, B\u00e4rfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69\u201378. https:\/\/doi.org\/10.1097\/fjc.0000000000000091.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"1177_CR39","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/ajh\/hpaa155","volume":"34","author":"K Kario","year":"2021","unstructured":"Kario K, Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, et al. Effect of the nonsteroidal mineralocorticoid receptor blocker, esaxerenone, on nocturnal hypertension: a post hoc analysis of the ESAX-HTN study. Am J Hypertens. 2021;34(5):540\u201351. https:\/\/doi.org\/10.1093\/ajh\/hpaa155.","journal-title":"Am J Hypertens"},{"issue":"10","key":"1177_CR40","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/s41440-019-0270-2","volume":"42","author":"H Itoh","year":"2019","unstructured":"Itoh H, Ito S, Rakugi H, Okuda Y, Nishioka S. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. Hypertens Res. 2019;42(10):1572\u201381. https:\/\/doi.org\/10.1038\/s41440-019-0270-2.","journal-title":"Hypertens Res"},{"issue":"4","key":"1177_CR41","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41440-020-00570-5","volume":"44","author":"F Satoh","year":"2021","unstructured":"\u2022 Satoh F, Ito S, Itoh H, Rakugi H, Shibata H, Ichihara A, et al. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism. Hypertens Res. 2021;44(4):464\u201372. https:\/\/doi.org\/10.1038\/s41440-020-00570-5. This paper demonstrates the mineralocorticoid receptor-blocking effect of esaxerenone in primary aldosteronism.","journal-title":"Hypertens Res"},{"key":"1177_CR42","doi-asserted-by":"publisher","unstructured":"Filippatos G, Anker SD, B\u00f6hm M, Gheorghiade M, K\u00f8ber L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016;37(27):2105\u201314. https:\/\/doi.org\/10.1093\/eurheartj\/ehw132.","DOI":"10.1093\/eurheartj\/ehw132"},{"key":"1177_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-021-02075-y","author":"S Ito","year":"2021","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study. Clin Exp Nephrol. 2021. https:\/\/doi.org\/10.1007\/s10157-021-02075-y.","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"1177_CR44","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41440-020-00606-w","volume":"44","author":"T Naruke","year":"2021","unstructured":"Naruke T, Maemura K, Oki T, Yazaki M, Fujita T, Ikeda Y, et al. Efficacy and safety of esaxerenone in patients with hypertension and concomitant heart failure. Hypertens Res. 2021;44(5):601\u20133. https:\/\/doi.org\/10.1038\/s41440-020-00606-w.","journal-title":"Hypertens Res"},{"issue":"9","key":"1177_CR45","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884\u201394. https:\/\/doi.org\/10.1001\/jama.2015.10081.","journal-title":"JAMA"},{"issue":"6","key":"1177_CR46","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/circulationaha.120.051898","volume":"143","author":"G Filippatos","year":"2021","unstructured":"Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021;143(6):540\u201352. https:\/\/doi.org\/10.1161\/circulationaha.120.051898.","journal-title":"Circulation"},{"issue":"1","key":"1177_CR47","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s12325-019-01121-2","volume":"37","author":"A Kurata","year":"2020","unstructured":"Kurata A, Yoshida T, Inoue M, Ishizuka T, Nakatsu T, Shimizu T, et al. Pharmacokinetics and safety of single-dose esaxerenone in japanese subjects with mild to moderate hepatic impairment. Adv Ther. 2020;37(1):253\u201364. https:\/\/doi.org\/10.1007\/s12325-019-01121-2.","journal-title":"Adv Ther"},{"issue":"5","key":"1177_CR48","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s13318-019-00547-x","volume":"44","author":"R Heinig","year":"2019","unstructured":"Heinig R, Lambelet M, Nagelschmitz J, Alatrach A, Halabi A. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94\u20138862) in individuals with mild or moderate hepatic impairment. Eur J Drug Metab Pharmacokinet. 2019;44(5):619\u201328. https:\/\/doi.org\/10.1007\/s13318-019-00547-x.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1177_CR49","doi-asserted-by":"publisher","unstructured":"Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991\u20131006. https:\/\/doi.org\/10.1161\/circresaha.116.305697.","DOI":"10.1161\/circresaha.116.305697"},{"issue":"Suppl 6","key":"1177_CR50","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1097\/00005344-199219006-00013","volume":"19","author":"PR Saxena","year":"1992","unstructured":"Saxena PR. Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems. J Cardiovasc Pharmacol. 1992;19(Suppl 6):S80\u20138. https:\/\/doi.org\/10.1097\/00005344-199219006-00013.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"1177_CR51","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/circulationaha.105.539122","volume":"112","author":"M Quinkler","year":"2005","unstructured":"Quinkler M, Zehnder D, Eardley KS, Lepenies J, Howie AJ, Hughes SV, et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation. 2005;112(10):1435\u201343. https:\/\/doi.org\/10.1161\/circulationaha.105.539122.","journal-title":"Circulation"},{"issue":"6","key":"1177_CR52","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1681\/asn.2011070734","volume":"23","author":"W Kawarazaki","year":"2012","unstructured":"Kawarazaki W, Nagase M, Yoshida S, Takeuchi M, Ishizawa K, Ayuzawa N, et al. Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J Am Soc Nephrol. 2012;23(6):997\u20131007. https:\/\/doi.org\/10.1681\/asn.2011070734.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1177_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1161\/hypertensionaha.115.06054","volume":"67","author":"N Ayuzawa","year":"2016","unstructured":"Ayuzawa N, Nagase M, Ueda K, Nishimoto M, Kawarazaki W, Marumo T, et al. Rac1-mediated activation of mineralocorticoid receptor in pressure overload-induced cardiac injury. Hypertension. 2016;67(1):99\u2013106. https:\/\/doi.org\/10.1161\/hypertensionaha.115.06054.","journal-title":"Hypertension"},{"issue":"3\u20135","key":"1177_CR54","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jsbmb.2007.03.020","volume":"104","author":"DJ Morris","year":"2007","unstructured":"Morris DJ, Latif SA, Hardy MP, Brem AS. Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol. J Steroid Biochem Mol Biol. 2007;104(3\u20135):161\u20138. https:\/\/doi.org\/10.1016\/j.jsbmb.2007.03.020.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1177_CR55","doi-asserted-by":"publisher","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709\u201317. https:\/\/doi.org\/10.1056\/NEJM199909023411001.","DOI":"10.1056\/NEJM199909023411001"},{"issue":"4","key":"1177_CR56","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839\u201345. https:\/\/doi.org\/10.1161\/01.HYP.0000259805.18468.8c.","journal-title":"Hypertension"},{"issue":"2","key":"1177_CR57","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40257-016-0245-x","volume":"18","author":"AM Layton","year":"2017","unstructured":"Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. Am J Clin Dermatol. 2017;18(2):169\u201391. https:\/\/doi.org\/10.1007\/s40257-016-0245-x.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1177_CR58","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00380-018-1250-1","volume":"34","author":"M Yamamoto","year":"2019","unstructured":"Yamamoto M, Seo Y, Ishizu T, Nishi I, Hamada-Harimura Y, Machino-Ohtsuka T, et al. Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure. Heart Vessels. 2019;34(2):279\u201389. https:\/\/doi.org\/10.1007\/s00380-018-1250-1.","journal-title":"Heart Vessels"},{"issue":"8","key":"1177_CR59","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/s0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15(8):709\u201316. https:\/\/doi.org\/10.1016\/s0895-7061(02)02957-6.","journal-title":"Am J Hypertens"},{"issue":"9","key":"1177_CR60","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/s2213-8587(20)30218-7","volume":"8","author":"I Bancos","year":"2020","unstructured":"Bancos I, Taylor AE, Chortis V, Sitch AJ, Jenkinson C, Davidge-Pitts CJ, et al. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol. 2020;8(9):773\u201381. https:\/\/doi.org\/10.1016\/s2213-8587(20)30218-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1177_CR61","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1373\/clinchem.2015.251199","volume":"62","author":"G Eisenhofer","year":"2016","unstructured":"Eisenhofer G, Dekkers T, Peitzsch M, Dietz AS, Bidlingmaier M, Treitl M, et al. Mass spectrometry-based adrenal and peripheral venous steroid profiling for subtyping primary aldosteronism. Clin Chem. 2016;62(3):514\u201324. https:\/\/doi.org\/10.1373\/clinchem.2015.251199.","journal-title":"Clin Chem"},{"key":"1177_CR62","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cca.2017.05.002","volume":"470","author":"G Eisenhofer","year":"2017","unstructured":"Eisenhofer G, Peitzsch M, Kaden D, Langton K, Pamporaki C, Masjkur J, et al. Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS\/MS: impact of gender, age, oral contraceptives, body mass index and blood pressure status. Clin Chim Acta. 2017;470:115\u201324. https:\/\/doi.org\/10.1016\/j.cca.2017.05.002.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"1177_CR63","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","volume":"25","author":"T Wada","year":"2021","unstructured":"Wada T, Inagaki M, Yoshinari T, Terata R, Totsuka N, Gotou M, et al. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. Clin Exp Nephrol. 2021;25(2):120\u201330. https:\/\/doi.org\/10.1007\/s10157-020-01963-z.","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"1177_CR64","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/cts.12705","volume":"13","author":"A Whittaker","year":"2020","unstructured":"Whittaker A, Kragh \u00c5M, Hartleib-Geschwindner J, Albayaty M, Backlund A, Greasley PJ, et al. Safety, tolerability, and pharmacokinetics of the mineralocorticoid receptor modulator AZD9977 in healthy men: a phase i multiple ascending dose study. Clin Transl Sci. 2020;13(2):275\u201383. https:\/\/doi.org\/10.1111\/cts.12705.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1177_CR65","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/hypertensionaha.121.17073","volume":"78","author":"G Bakris","year":"2021","unstructured":"Bakris G, Pergola PE, Delgado B, Genov D, Doliashvili T, Vo N, et al. Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study. Hypertension. 2021;78(1):74\u201381. https:\/\/doi.org\/10.1161\/hypertensionaha.121.17073.","journal-title":"Hypertension"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-022-01177-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-022-01177-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-022-01177-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T06:20:31Z","timestamp":1658298031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-022-01177-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1177"],"URL":"https:\/\/doi.org\/10.1007\/s11906-022-01177-6","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,30]]},"assertion":[{"value":"21 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Yuta Tezuka and Sadayoshi Ito declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}